![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Adis International Limited
Publisher: Adis International
ISSN: 1172-0360
Source: Drugs & Therapy Perspectives, Vol.23, Iss.10, 2007-10, pp. : 9-13
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
By Bitter I. Dossenbach M.R.K. Brook S. Feldman P.D. Metcalfe S. Gagiano C.A. Furedi J. Bartko G. Janka Z. Banki C.M. Kovacs G. Breier A. for the Olanzapine HGCK Study Group
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 28, Iss. 1, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Ziprasidone effective in treatment-resistant schizophrenia
Inpharma, Vol. 1, Iss. 1522, 2006-01 ,pp. :